These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21542898)

  • 1. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.
    Muranen TA; Greco D; Fagerholm R; Kilpivaara O; Kämpjärvi K; Aittomäki K; Blomqvist C; Heikkilä P; Borg A; Nevanlinna H
    Breast Cancer Res; 2011 Sep; 13(5):R90. PubMed ID: 21542898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
    BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
    Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
    Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
    Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
    Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
    Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
    Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
    Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
    Chen W; Yurong S; Liansheng N
    Adv Ther; 2008 May; 25(5):496-501. PubMed ID: 18484200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
    Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
    Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.
    Thirthagiri E; Cheong LS; Yip CH; Teo SH
    Fam Cancer; 2009; 8(4):355-8. PubMed ID: 19399639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum.
    Isinger A; Bhat M; Borg A; Nilbert M
    BMC Cancer; 2006 Mar; 6():64. PubMed ID: 16539695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
    Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.